Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06557057 · ClinicalTrials.gov registry record

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

A clinical trial of HER2-Positive Breast Carcinoma, sponsored by Mayo Clinic.

Recruiting
Registry status
66
Enrollment target
1
Study location

NCT06557057: Recruiting study of HER2-Positive Breast Carcinoma, sponsored by Mayo Clinic.

NCT06557057 is a study of HER2-Positive Breast Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 66 participants, below the 162-participant average among 12 other HER2-Positive Breast Carcinoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06557057, a study of HER2-Positive Breast Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
66 participants
Enrollment target
1
Study location

Study Summary

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Primary Outcome

Will be calculated as the product of beta cell responsivity and Si (insulin action). DI of women with hormone receptor positive breast cancer or DCIS treated with aromatase inhibitors will be compared to DI of healthy post menopausal women. Participants will undergo a history, physical examination, and a blood collection for fasting glucose, and Hemoglobin A1C (HbA1c) at baseline and one year later. Participants will be contacted at 3 and 6 months by phone to confirm continued use of the endocri

Conditions Studied

HER2-Positive Breast Carcinoma

Interventions

  • OTHER Non-Interventional Study

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2023-11-16
Est. Completion 2026-12-01
Mayo Clinic

2,844 total trials

What NCT06557057 shows while recruiting

NCT06557057 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 162-participant average among 12 other HER2-Positive Breast Carcinoma trials with a reported enrollment target (59% lower).

The record links to 1 condition, with HER2-Positive Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT06557057 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06557057 about?

NCT06557057 is a clinical study titled "Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk". This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

What is the current status of trial NCT06557057?

This trial is currently recruiting. The enrollment target is 66 participants. The study started on 2023-11-16. Estimated completion is 2026-12-01.

What conditions does trial NCT06557057 study?

This clinical trial studies the following conditions: HER2-Positive Breast Carcinoma.

What interventions are being tested in trial NCT06557057?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT06557057?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06557057 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HER2-Positive Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06557057's enrollment target sits among peer trials

66 6th of 12 higher than 7 of 12 other HER2-Positive Breast Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HER2-Positive Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02584244 · 66 participants · Phase 1

    Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

  • NCT03067051 · 66 participants · Phase 1

    Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

  • NCT03754725 · 66 participants · Phase 1

    Ferritin and Iron Burden in SAH sIRB

  • NCT03875378 · 66 participants · Phase 2

    Transdermal Estrogen in Women With Anorexia Nervosa

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06557057

Source: ClinicalTrials.gov NCT06557057, the US trial registry maintained by the National Library of Medicine. NCT06557057 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.